Oral PCS499 Improves Skin Activity and Ulcer Healing in Necrobiosis Lipoidica

The therapeutic challenge of necrobiosis lipoidica

Necrobiosis lipoidica is a rare, chronic granulomatous skin disease characterized by collagen degeneration and a high risk of painful, recalcitrant ulceration [1, 2]. Despite the significant morbidity and the risk of permanent scarring associated with these lesions, there are currently no treatments approved by the US Food and Drug Administration for this condition [2]. Clinicians frequently manage these patients using a variety of off-label interventions, including topical corticosteroids, calcineurin inhibitors, and phototherapy, but many cases remain resistant to these standard modalities [1]. The recurring nature of the disease and its frequent association with systemic comorbidities like diabetes mellitus necessitate the development of more reliable systemic therapies [1, 2]. To address this gap, researchers recently evaluated PCS499, an oral deuterated pentoxifylline analog (a chemically modified version of the drug designed to improve metabolic stability), to determine its safety and clinical efficacy for patients with treatment-resistant lesions.

Trial design and the deuterated analog mechanism

The investigation focused on PCS499, an oral deuterated pentoxifylline analog. In this chemical configuration, specific hydrogen atoms are replaced with deuterium, a heavier isotope, to create a compound with improved metabolic stability and a potentially enhanced safety profile compared to the parent drug. This phase 2, open-label nonrandomized clinical trial was conducted between January 2019 and February 2020 at the dermatology research centers of the University of Pennsylvania and the University of Pittsburgh. The study protocol involved a 6-month treatment period with an optional 6-month extension, during which participants received PCS499 at a dosage of 900 mg, administered orally twice daily.

The trial enrolled 12 participants with a median age of 41 years (range, 19 to 66 years). Notably, all 12 participants were female, and 10 of these individuals (83%) had a concurrent diagnosis of diabetes, a common comorbidity in this patient population. The study cohort presented with long-standing disease, evidenced by a mean disease duration of 12.7 years (SD, 9.3 years). To ensure the inclusion of patients with a significant clinical burden, eligibility required adults aged 18 to 80 years to have biopsy-confirmed necrobiosis lipoidica with a reference lesion of at least 10 square centimeters. Additionally, patients had to demonstrate active disease, defined as an Investigator Global Assessment of necrobiosis lipoidica activity score of 2 or greater on a scale of 0 to 5.

Strict exclusion criteria were implemented to isolate the effects of the study drug and ensure patient safety. The researchers excluded candidates who had recently used corticosteroids, immunosuppressants, biologics, phototherapy, or any pentoxifylline-class medications. Furthermore, individuals with significant comorbidities, as well as those who were pregnant or lactating, were ineligible for participation. By establishing these parameters, the study aimed to evaluate the safety and exploratory efficacy of this oral agent in a population that frequently lacks effective systemic options for managing chronic, large-scale lesions.

Clinical efficacy and ulcer resolution

The researchers utilized several exploratory efficacy end points to measure the clinical impact of PCS499. Six participants (50%) achieved a status of clear or almost clear on the Investigator Global Assessment, a standardized measure of overall disease severity. The median time to reach this level of clinical improvement was 111 days, with a range of 54 to 166 days. Statistical analysis of the Investigator Global Assessment activity scores showed a median change from baseline of -1.5 (interquartile range [IQR], -2.0 to 0.0; P = .03), indicating a measurable reduction in the clinical signs of active disease.

For clinicians managing the most severe complications of necrobiosis lipoidica, the results regarding ulcerated disease offer a potential new avenue for tissue healing. Two participants (17%) presented with ulcerated lesions at baseline, and both achieved complete ulcer closure by day 85 and day 351, respectively, without subsequent recurrence. Beyond ulcer healing, the study tracked changes in the physical characteristics of the lesions using the Necrobiosis Lipoidica Color and Ulcer Scale, a tool that quantifies inflammation and skin thickening. The researchers reported a median change in inflammation and color of -1.0 (IQR, -1.8 to 0.0; P = .02) and a median change in induration (the localized hardening or thickening of the skin) of -1.0 (IQR, -2.0 to 0.0; P = .04). These metrics suggest that the treatment may directly address the underlying granulomatous process that leads to skin breakdown and scarring.

The clinical improvements observed by investigators were mirrored in broader assessments of disease state and patient function. The Physician Global Assessment, which reflects the clinician's overall perception of the patient's condition, showed a median change of -1.3 (IQR, -2.8 to -0.9; P = .04). Furthermore, the impact on the daily lives of the participants was captured through the Skindex-29, a validated instrument for measuring the effects of skin disease on quality of life. The Skindex-29 function scores showed a median change of -14.6 (IQR, -27.1 to 3.1; P = .05). For practicing dermatologists and internists, these functional improvements suggest that the reduction in lesion activity and the resolution of ulcers translate directly into better physical and social functioning for patients.

Safety profile and tolerability

The researchers conducted a comprehensive safety assessment of the 900 mg twice daily PCS499 regimen through continuous adverse event monitoring, regular laboratory testing, and electrocardiograms. Data analysis indicated that the treatment was well tolerated by the cohort. No serious adverse events occurred during the study period, and the investigators reported no clinically significant laboratory abnormalities. For clinicians, this safety profile suggests that the deuterated pentoxifylline analog does not induce the systemic toxicities or metabolic disturbances often associated with long-term immunosuppressive therapies used off-label for necrobiosis lipoidica.

The most frequently reported side effect was mild gastrointestinal symptoms, which occurred in 33% of participants. These symptoms did not lead to significant attrition, as 10 of the 12 participants (83%) successfully completed the full treatment course. This high completion rate in a population with a mean disease duration of 12.7 years and a high prevalence of diabetes (83%) provides a preliminary indication of the drug's suitability for chronic management. While these exploratory findings are encouraging, the researchers concluded that larger, randomized trials are warranted to confirm the safety and efficacy of PCS499 in a broader clinical population before it can be routinely integrated into standard practice.

References

1. Nihal A, Caplan AS, Rosenbach M, Damsky W, Mangold AR, Shields BE. Treatment options for necrobiosis lipoidica: a systematic review. International Journal of Dermatology. 2023. doi:10.1111/ijd.16856

2. Rubenstein AI, Das M, Nyberg M, et al. Deuterated Pentoxifylline Analog in the Treatment of Necrobiosis Lipoidica: A Nonrandomized Clinical Trial.. JAMA dermatology. 2026. doi:10.1001/jamadermatol.2026.0863